Utility of 18F-FDG PET with a Semi-Quantitative Index in the Detection of Sarcomatous Transformation in Patients with Neurofibromatosis Type 1

P. Combemale(Centre Léon Bérard), Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), P. Wolkenstein(Université Paris-Est Créteil), Jean‐Yves Blay(Université Claude Bernard Lyon 1), L. Valeyrie‐Allanore, B. Guillot(Université de Montpellier), Francesco Giammarile(International Atomic Energy Agency), Denis Mariano‐Goulart(Centre Hospitalier Universitaire de Montpellier), S. Pinson(Hôpital Edouard Herriot)
PLoS ONE
February 6, 2014
10.1371/journal.pone.0085954
Cited by 60

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978